Anne Wojcicki’s winning bid to reclaim control of 23andMe doesn’t necessarily end the fight over what happens to the DNA of ...

Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning ...

Anne Wojcicki's winning bid to reclaim control of 23andMe doesn't necessarily end the fight over what happens to the DNA of ...

A nonprofit led by the co-founder and former CEO of 23andMe outbid competitors for nearly all of the company’s assets.

Former 23andMe CEO Anne Wojcicki outbids Regeneron with a $305 million offer through her nonprofit TTAM to regain control of the DNA-testing company she co-founded.

A nonprofit run by Anne Wojcicki, the cofounder and former CEO of 23andme, has agreed to buy the genetic testing company for ...

California says the sale of 23andMe to a nonprofit formed by the company's former CEO would skirt a state law specifically ...

In a recent investigation we took a hard look at the cybersecurity practices of major direct-to-consumer DNA testing ...

The FTSE 100 faces a stern test of its new high levels this week, with Israel-Iran tensions still running high and Tehran ...

Regeneron Pharmaceuticals (NASDAQ:REGN) has reportedly declined to submit a higher bid for 23andMe (OTC:MEHCQ) after a ...

TTAM Research Institute - 23andMe's co-founder and former CEO Anne Wojcicki's new company - is the winner in a final round of ...